

# Marrone Bio Innovations

10:35 11 Jul 2019

## Marrone Bio and plant-nutrient producer Valagro announce R&D partnership

Marrone Bio Innovations Inc (NASDAQ:MBII) announced Thursday it has entered into a strategic partnership with Valagro S.p.A of Italy, a leader in the production and commercialization of biostimulants and specialty nutrients.

The California-based developer of bio-based products for pest management and plant health said that under the research and development collaboration agreement both companies will leverage a subset of Marrone Bio's collection of 18,000 microorganisms in conjunction with Valagro's products that enhance crop yield and quality.

### READ: California farmers embrace Marrone Bio Innovations' BioUnite pest control program

Products resulting from this partnership have the potential to enhance a grower's productivity and return on investment with plants that develop better root systems, grow with more vigor and thrive under harsher growing conditions, Marrone Bio said in a statement.

Additionally, growers of specialty crops would have the potential to produce higher quality fruit that matures more quickly.

"As a leader in the plant biostimulants development space, Valagro is excited to combine our unique know-how acquired in the field of plant biostimulants and plant nutrition with Marrone Bio's strength in microorganisms and biopesticides, addressing a \$155 billion global plant nutrition market," said Valagro CEO Giuseppe Natale.

Marrone CEO Dr Pam Marrone said the Valagro partnership will "further monetize our microorganism collection, applying our biologicals expertise into adjacent markets. The products from this partnership have the potential to provide growers with innovative new products addressing unmet needs."

Contact the author: [patrick@proactiveinvestors.com](mailto:patrick@proactiveinvestors.com)

Follow him on Twitter @PatrickMGraham

**Price:** 1.1

**Market Cap:** \$167.72 m

### 1 Year Share Price Graph



October 2019    May 2020    October 2020

### Share Information

**Code:** MBII

**Listing:** NASDAQ

<b>52 week</b>	<b>High</b>	<b>Low</b>
	1.5	0.6104

**Sector:** Agribusiness

**Website:** [www.marronebioinnovations.com](http://www.marronebioinnovations.com)

### Company Synopsis:

*Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth company leading the movement to more a sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that help customers operate more sustainably while increasing their return on investment.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Marrone Bio Innovations named herein, including the promotion by the Company of Marrone Bio Innovations in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).